Pharmaceutical company Pfizer confirmed on Tuesday that clinical trials show that its anti-COVID pill reduced hospitalisations and deaths among at risk people by around 90%.
The results are based on trials of more than 2,200 people, backing up findings announced last month from preliminary trials. Pfizer also confirmed that the treatment appears to be effective agains the newly discovered Omicron variant.
Pfizer CEO Albert Bourla said that the new drug, called Paxlovid, could save lives and provides further corroboration that the oral antiviral could have a meaningful impact on the lives of many.
Trials showed that the pill reduced the need for hospitalisation in high-risk adults by 89% if the treatment was given within three days of symptom onset and 88% within 5 days.
Bourla said that Pfizer are confident that, if authorised or approved, ‘this potential treatment could be a critical tool to help quell the pandemic.’
#MaltaDaily
Photo Source: TRT World